C-Rad AB (publ) CRAD.B
Free
No email, no account, no signup.
General analysis — not personal advice.
Bull
Bear
Want to follow C-Rad AB (publ)? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Exchange
Stockholm
Type
Technology
Sector
Surface Image Guided Radiation Therapy
Price & valuation
Last close
SEK 36.20
1 week
+2.3 %
3 months
+6.8 %
12 months
+8.7 %
From 52w high
-6.7 %
From 52w low
+45.4 %
We're already tracking C-Rad AB (publ) — here are the latest events we've registered
Recent News
- On June 9, 2026, it was reported that CFO Linda Frölén purchased 22,000 shares in the company. During May 2026, C-Rad entered a partnership with SeeTreat for personalized radiotherapy and showcased new SGRT advances at the ESTRO 2026 congress. The Q1 2026 interim report showed a 19 percent increase in order intake compared to the same period last year.
What Firelda Watch includes for C-Rad AB (publ)
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — AI roundup of the week's news
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of C-Rad AB (publ) will be delivered in the same format.
Want to follow C-Rad AB (publ)? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.